{"id":46122,"date":"2022-07-13T14:01:53","date_gmt":"2022-07-13T12:01:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/"},"modified":"2022-07-13T14:01:53","modified_gmt":"2022-07-13T12:01:53","slug":"cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/","title":{"rendered":"Cognito Therapeutics Announces Data Presentations at the Alzheimer\u2019s Association International Conference 2022"},"content":{"rendered":"
\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–#AAIC2022<\/a>—Cognito Therapeutics<\/a>, a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, today announced the acceptance of two research abstracts and an oral presentation at the Alzheimer\u2019s Association International Conference\u00ae<\/sup> 2022 (AAIC\u00ae<\/sup>)<\/a>. The largest international meeting dedicated to advancing dementia science, AAIC will be held as an online and in-person event in San Diego, July 31- August 4, 2022.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe\u2019re excited to present our recent findings at AAIC which shows that 40Hz gamma sensory stimulation therapy for a 6-month period may reduce white matter atrophy, protect axons, and possibly prevent myelin and oligodendrocyte damage in Alzheimer\u2019s patients,\u201d said Brent Vaughan, Chief Executive Officer, Cognito Therapeutics. \u201cGiven the crucial role of white matter connecting expansive brain regions, preventing or reducing its atrophy may diminish disease progression. We look forward to sharing our results indicating that our therapy can potentially improve outcomes for patients with Alzheimer\u2019s and Mild Cognitive Impairment, as well as other neuro-degenerative diseases that involve loss of white matter and myelination.\u201d\n<\/p>\n

\nDetails of the presentations are as follows:\n<\/p>\n

\nPoster Title: Gamma-Frequency Sensory Stimulation is Safe and Well-Tolerated Treatment Option for Patients with Alzheimer\u2019s Disease<\/b>\n<\/p>\n

\nPresenting Author: Mihaly Haj\u00f3s, Pharm.D., Ph.D., et al.<\/i>\n<\/p>\n

\nDate: <\/b>Tuesday, <\/b>August 2, 2022\n<\/p>\n

\nPoster Title: Gamma Sensory Stimulation at 40Hz for a 6-month Period Reduces White Matter Atrophy in Alzheimer\u2019s Disease Patients<\/b>\n<\/p>\n

\nDate: <\/b>Sunday, July 31, 2022\n<\/p>\n

\nPresenting Author: Xiao Da, M.Sc., et al.<\/i>\n<\/p>\n

\nOral Presentation Title: Sensory stimulation improves daily functions in Alzheimer\u2019s disease<\/b>\n<\/p>\n

\nFeatured Research Session: Neuronal excitation\/inhibition imbalance contributes to Alzheimer\u2019s disease pathology and represents potential target for treatment\n<\/p>\n

\nPresenting Author: Aylin Cimenser, Ph.D., et al.<\/i>\n<\/p>\n

\nDate\/Time: <\/b>Thursday, <\/b>August 4, 2022, 10:30-10:45 am (PT)\n<\/p>\n

\nTo meet with the Cognito team on-site at AAIC, please contact aaic2022@cognitotx.com<\/a>.\n<\/p>\n

\nAbout Cognito Therapeutics\n<\/p>\n

\nCognito Therapeutics is a pioneer in disease-modifying therapeutic interventions for neurodegenerative diseases and human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic platform has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer\u2019s disease. Cognito has received FDA Breakthrough Device Designation for treatment of the cognitive and functional symptoms associated with Alzheimer’s disease in individuals diagnosed with mild to moderate Alzheimer\u2019s and expects to start pivotal studies in 2022. The company\u2019s technology is based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and optogenetics pioneer Ed Boyden at MIT. Cognito Therapeutics is based in Cambridge, MA. For more information, visit www.cognitotx.com<\/a>. Follow us on Twitter at @cognitotx.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia
\n
Kimberly Ha
\n
KKH Advisors
\n
917-291-5744
\n
kimberly.ha@kkhadvisors.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–#AAIC2022—Cognito Therapeutics, a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, today announced the acceptance of two research abstracts and an oral presentation at the Alzheimer\u2019s Association International Conference\u00ae 2022 (AAIC\u00ae). The largest international meeting dedicated to advancing dementia science, AAIC will be held as an online and in-person event in San … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46122","6":"format-standard","7":"category-industry"},"yoast_head":"\nCognito Therapeutics Announces Data Presentations at the Alzheimer\u2019s Association International Conference 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cognito Therapeutics Announces Data Presentations at the Alzheimer\u2019s Association International Conference 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.–(BUSINESS WIRE)–#AAIC2022—Cognito Therapeutics, a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, today announced the acceptance of two research abstracts and an oral presentation at the Alzheimer\u2019s Association International Conference\u00ae 2022 (AAIC\u00ae). The largest international meeting dedicated to advancing dementia science, AAIC will be held as an online and in-person event in San ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-13T12:01:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220713005304\/en\/1512174\/21\/full_-_gardient_-_dark_text%402x_%284%29_%281%29_%282%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cognito Therapeutics Announces Data Presentations at the Alzheimer\u2019s Association International Conference 2022\",\"datePublished\":\"2022-07-13T12:01:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\\\/\"},\"wordCount\":452,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005304\\\/en\\\/1512174\\\/21\\\/full_-_gardient_-_dark_text%402x_%284%29_%281%29_%282%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\\\/\",\"name\":\"Cognito Therapeutics Announces Data Presentations at the Alzheimer\u2019s Association International Conference 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005304\\\/en\\\/1512174\\\/21\\\/full_-_gardient_-_dark_text%402x_%284%29_%281%29_%282%29.jpg\",\"datePublished\":\"2022-07-13T12:01:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005304\\\/en\\\/1512174\\\/21\\\/full_-_gardient_-_dark_text%402x_%284%29_%281%29_%282%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005304\\\/en\\\/1512174\\\/21\\\/full_-_gardient_-_dark_text%402x_%284%29_%281%29_%282%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cognito Therapeutics Announces Data Presentations at the Alzheimer\u2019s Association International Conference 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cognito Therapeutics Announces Data Presentations at the Alzheimer\u2019s Association International Conference 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/","og_locale":"en_US","og_type":"article","og_title":"Cognito Therapeutics Announces Data Presentations at the Alzheimer\u2019s Association International Conference 2022 - Pharma Trend","og_description":"CAMBRIDGE, Mass.–(BUSINESS WIRE)–#AAIC2022—Cognito Therapeutics, a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, today announced the acceptance of two research abstracts and an oral presentation at the Alzheimer\u2019s Association International Conference\u00ae 2022 (AAIC\u00ae). The largest international meeting dedicated to advancing dementia science, AAIC will be held as an online and in-person event in San ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-13T12:01:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220713005304\/en\/1512174\/21\/full_-_gardient_-_dark_text%402x_%284%29_%281%29_%282%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cognito Therapeutics Announces Data Presentations at the Alzheimer\u2019s Association International Conference 2022","datePublished":"2022-07-13T12:01:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/"},"wordCount":452,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220713005304\/en\/1512174\/21\/full_-_gardient_-_dark_text%402x_%284%29_%281%29_%282%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/","url":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/","name":"Cognito Therapeutics Announces Data Presentations at the Alzheimer\u2019s Association International Conference 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220713005304\/en\/1512174\/21\/full_-_gardient_-_dark_text%402x_%284%29_%281%29_%282%29.jpg","datePublished":"2022-07-13T12:01:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220713005304\/en\/1512174\/21\/full_-_gardient_-_dark_text%402x_%284%29_%281%29_%282%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220713005304\/en\/1512174\/21\/full_-_gardient_-_dark_text%402x_%284%29_%281%29_%282%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-data-presentations-at-the-alzheimers-association-international-conference-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cognito Therapeutics Announces Data Presentations at the Alzheimer\u2019s Association International Conference 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46122"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46122\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}